Skip to main navigation
Skip to search
Skip to main content
Arizona Board of Regents Home
Search content at Arizona Board of Regents
Home
Profiles
Departments and Centers
Scholarly Works
Grants
Activities
Equipment
Datasets
Press/Media
Prizes
Celecoxib use and circulating oxylipins in a colon polyp prevention trial
Jessica A. Martinez
, Jun Yang
, Betsy C. Wertheim
, Denise J. Roe
, Alexander Schriewer
, Peter Lance
, David S. Alberts
, Bruce D. Hammock
, Patricia A. Thompson
Nutritional Sci Wellness - RES
Epidemiology and Biostatistics
Cancer Center Division
Research output
:
Contribution to journal
›
Article
›
peer-review
9
Link opens in a new tab
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Celecoxib use and circulating oxylipins in a colon polyp prevention trial'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Prevention Trials
100%
Colon Polyps
100%
Celecoxib
100%
Oxylipins
100%
Lipoxygenase
75%
Systolic Blood Pressure
50%
Arachidonic Acid
37%
Aspirin
37%
Arachidonic Acid Metabolism
37%
Hypertension
25%
Placebo
25%
Cytochrome P450 (CYP450)
25%
Cyclooxygenase-2
25%
Cyclooxygenase-1 (COX-1)
25%
Selenium
12%
Patient Samples
12%
Potential Adverse Effects
12%
Daily Use
12%
Randomized Placebo-controlled Trial
12%
Anti-inflammatory Agents
12%
Bioactive
12%
Pharmacological Inhibitors
12%
Joint Pain
12%
Prostaglandin E2
12%
Muscle Pain
12%
Blood Pressure Control
12%
Plasma Concentration
12%
N-95
12%
Cyclooxygenase-2 Inhibitors
12%
Cytochrome P450 Enzymes
12%
Androgen-independent
12%
Gastrointestinal Toxicity
12%
Colorectal Adenomatous Polyps
12%
Low-dose Aspirin
12%
Cardiovascular Toxicity
12%
Oxygenated Fatty Acids
12%
20-hydroxyeicosatetraenoic Acid (20-HETE)
12%
Cytochrome P450 Metabolites
12%
Pharmacology, Toxicology and Pharmaceutical Science
Celecoxib
100%
Colon Polyp
100%
Oxylipin
100%
Arachidonic Acid
62%
Lipoxygenase
62%
Acetylsalicylic Acid
50%
Cytochrome P450
50%
Placebo
37%
Prostaglandin Synthase
25%
Cyclooxygenase 2
25%
Androgen
12%
Adverse Event
12%
Antiinflammatory Agent
12%
Adenomatous Polyp
12%
COX-2 Inhibitor
12%
Prostaglandin E2
12%
Myalgia
12%
Arthralgia
12%
Gastrointestinal Toxicity
12%
Lipid
12%
20 Hydroxyicosatetraenoic Acid
12%
Cardiovascular Toxicity
12%
Arachidonate Lipoxygenase
12%
Neuroscience
Oxylipin
100%
Celecoxib
100%
Arachidonic Acid
62%
Lipoxygenase
62%
Cytochrome P450
50%
Aspirin
50%
Placebo
37%
Metabolic Pathway
37%
Cyclooxygenase 2
25%
Cyclooxygenase
25%
Androgen
12%
Adverse Effect
12%
COX-2 Inhibitor
12%
Prostaglandin E2
12%
Anti-Inflammatory Agent
12%
Lipid
12%
Myalgia
12%
Arachidonate Lipoxygenase
12%
20 Hydroxyicosatetraenoic Acid
12%
Blood Plasma
12%
Hypertension
12%